ArticleNature2013
Immune clearance of highly pathogenic SIV infection.
Article in Nature, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 417 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
417 citing papers in PubMed, 615 citations in OpenAlex.
- Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species.PLoS pathogens · 2022Trial
- CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.Frontiers in immunology · 2021Trial
- Antigenic competition in CD4Science translational medicine · 2019Trial
- Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation.The Journal of clinical investigation · 2019Trial
- SIV reservoir depletion and clearance from neonatal macaques following transient CCR5 depletion.Nature microbiology · 2026Article
- Antiviral and anti-inflammatory effects of Cannabidiol in HIV/SIV infection.Brain, behavior, and immunity · 2026Article
- Spondweni virus infection in pregnant rhesus macaques causes placental pathology without apparent fetal harm.bioRxiv : the preprint server for biology · 2026Article
- HLA-E-restricted T cells primed by a modified HLA-B*57:01-restricted HIV-1 peptide suppress HIV-1 replication.JCI insight · 2026Article
- Durable protection against SIV challenge by adeno-associated virus delivery of Env-specific antibodies.bioRxiv : the preprint server for biology · 2026Article
- α4 Integrin blockade impairs CD8+ T cell neuroimmune surveillance following SIV infection.The Journal of clinical investigation · 2026Article
- Dissecting the steps in early simian immunodeficiency virus dissemination following mucosal and intravenous infection of rhesus macaques.Journal of virology · 2026Article
- Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound.The Journal of clinical investigation · 2026Article
- Non-cognate CD8 Binding to MHC I Promotes Positive Selection of an MHC-E Restricted CD8 T Cell Population.European journal of immunology · 2026Article
- Initial sites of SIV rebound after antiretroviral treatment cessation in rhesus macaques.Nature microbiology · 2026Article
- Prenatal Zika virus exposure disrupts social-emotional development and cortical visual function in infant macaques.Nature communications · 2026Article
- T cell antigenic recognition sequencing (TAR-seq) enables precise characterization of vaccine-elicited cellular immunity ex vivo andFrontiers in immunology · 2026Article
- Targeting MHC-E as a new strategy for vaccines and immunotherapeutics.Nature reviews. Immunology · 2026Review
- Resolving inflammation: The impact of antiretroviral therapy on macrophage traffic in and out of the CNS.PLoS pathogens · 2025Article
- The TLR7 agonist vesatolimod does not measurably induce SIV expression in macaques receiving combination antiretroviral therapy initiated during chronic infection.Antimicrobial agents and chemotherapy · 2025Article
- Novel Perineural Pathways and the Dynamics of SIV-Infected Macrophage Trafficking Out of the Central Nervous System.The American journal of pathology · 2025Article
357 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
26 authors at 4 institutions in 2 countries.
Funding
Abstract
Established infections with the human and simian immunodeficiency viruses (HIV and SIV, respectively) are thought to be permanent with even the most effective immune responses and antiretroviral therapies only able to control, but not clear, these infections. Whether the residual virus that maintains these infections is vulnerable to clearance is a question of central importance to the future management of millions of HIV-infected individuals. We recently reported that approximately 50% of rhesus macaques (RM; Macaca mulatta) vaccinated with SIV protein-expressing rhesus cytomegalovirus (RhCMV/SIV) vectors manifest durable, aviraemic control of infection with the highly pathogenic strain SIVmac239 (ref. 5). Here we show that regardless of the route of challenge, RhCMV/SIV vector-elicited immune responses control SIVmac239 after demonstrable lymphatic and haematogenous viral dissemination, and that replication-competent SIV persists in several sites for weeks to months. Over time, however, protected RM lost signs of SIV infection, showing a consistent lack of measurable plasma- or tissue-associated virus using ultrasensitive assays, and a loss of T-cell reactivity to SIV determinants not in the vaccine. Extensive ultrasensitive quantitative PCR and quantitative PCR with reverse transcription analyses of tissues from RhCMV/SIV vector-protected RM necropsied 69-172 weeks after challenge did not detect SIV RNA or DNA sequences above background levels, and replication-competent SIV was not detected in these RM by extensive co-culture analysis of tissues or by adoptive transfer of 60 million haematolymphoid cells to naive RM. These data provide compelling evidence for progressive clearance of a pathogenic lentiviral infection, and suggest that some lentiviral reservoirs may be susceptible to the continuous effector memory T-cell-mediated immune surveillance elicited and maintained by cytomegalovirus vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.